MARKET WIREYahoo! Finance Canada • 22h ago
Medpace Holdings, Inc. (MEDP) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
Why MEDP Stock slipped -0.59% Today — RQD Quant Desk Flash
$648.14 -0.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $649.01
Medpace Holdings Inc. (MEDP) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (steady margins, 28% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B+ • BUY
Cap $18.24B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MEDP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MEDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Medpace Holdings Inc. (NASDAQ: MEDP) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $648.14 (-0.59% 1D, market cap $18.24B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, MEDP ranks #24 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MEDP compare to CRL and ICLR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), MEDP carries a Roarable B+ (77/100 RQD), trailing P/E of 42.0x, gross margin of —, and ROIC of 27.9%. By comparison, CRL (Charles River Laboratories International Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 0.4%, cap $17.16B) and ICLR (ICON plc) posts a B grade (72/100 RQD, P/E 71.9x, ROIC 3.1%, cap $16.18B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MEDP?
▼
Per MEDP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001668397), Medpace Holdings Inc. generated $2.53B in revenue (+20.0% YoY), $451.1M in net income, and $681.9M in free cash flow against $1.98B in total assets and $682.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 42x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $648.98 (+0.13%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 26.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B+
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw A- · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE+8.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MEDP)Realized 20D OHLCV Swing Band: ±7.2%
Deterministic 5-Pillar Attribution (77/100 Composite)
🔍 WHY MEDP SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 26.9% FCF Margin ($681.9M FCF) & 52% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (21% of score)
Altman Z-Score 9.13 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)
Macro rate sensitivity & RSI-14 (52.4) create a -9 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$616.63+7.4% Next Q
69
Q2 (-2Q)Grade B$662.48+4.6% Next Q
72
Q3 (-1Q)Grade B+$692.68-6.4% Next Q
74
CurrentGrade B+$648.14+7.8% Hist 90D α
77
Trajectory: B- (69) → B+ (77)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the MEDP Bull Thesis Could Fail
Even with a 77/100 (B+) score, MEDP faces multiple-compression risk if 42.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Priced at 42x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($622.17) or 200D SMA ($530.25) invalidates the momentum regime and cuts Target Base ($703.56) toward Bear Floor ($531.47).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MEDP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MEDP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MEDP Stock slipped -0.59% Today — RQD Quant Desk Flash
Medpace Holdings Inc. (MEDP) slipped -0.59% to $648.14, trading at 86% of its 52-week range ($373 – $693.97). High-quality cash engine (steady margins, 28% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 86% of its 52-week range ($373 – $693.97) with RSI-14 at 52.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.2% around $648.14 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B+ (Buy) backed by 52% gross margin and $681.9M annual free cash flow.
Live MEDP Headlines & Catalysts
RISK WATCHInvestor's Business Daily • 1d ago
Medpace Slumps On Solid Report — Where Are The 'Holes?'Investor's Business Daily report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Here’s How Much You Would Have Made Owning Medpace Holdings Stock In The Last 10 YearsBenzinga report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 1d ago
Medpace: Strong Execution Faces A High-Growth Bar (NASDAQ:MEDP)Seeking Alpha report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance UK • 1d ago
Medpace (MEDP) Stock Declines While Market Improves: Some Information for InvestorsYahoo Finance UK report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Medpace (NASDAQ:MEDP) reports Q3 2026 in line with expectationsTradingView report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One (NASDAQ:MEDP)Seeking Alpha report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
What To Expect From Medpace’s (MEDP) Q3 EarningsYahoo Finance report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 3d ago
2 high-flying stocks on our watchlist and 1 we turn downExpensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room
MARKET WIREYahoo • 3d ago
Medpace (MEDP) is a Great Momentum Stock: Should You Buy?Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (MEDP Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MEDP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.42%▲ ASCENDING CHANNEL
2026-11-03O $677.6H $677.6L $648.1C $648.1VOL 219.6K
RES: $700.8SUP: $600.5SMA50: $622.2SMA200: $530.3
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MEDP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
31.7%/yr Implied 5Y Growth
vs. +20.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on MEDP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MEDP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MEDP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MEDP)
Health Care Rank #24 of 1015
⚔️ CRL vs MEDP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MEDP vs. CRL, ICLR, INCY, IQV)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Medpace Holdings Inc. (MEDP) ranks #24 by composite RQD confidence (77/100, grade B+) and #71 by equity capitalization ($18.24B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 88/100 (A) compared with MEDP at 77/100 (B+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MEDP
ACTIVE
Medpace Holdings Inc. | B+ | 77/100 | 42.0x | — | 27.9% | -0.59% | $18.24B | Benchmark Subject |
| CRL Charles River Laboratories International Inc. | C | 64/100 | — | — | 0.4% | -5.81% | $17.16B | /crl-vs-medp → |
| ICLR ICON plc | B | 72/100 | 71.9x | — | 3.1% | -2.94% | $16.18B | /iclr-vs-medp → |
| INCY Incyte Corp. | A | 88/100 | 18.4x | 92.8% | 42.4% | -0.29% | $24.54B | /incy-vs-medp → |
| IQV IQVIA Holdings Inc. | C- | 61/100 | 33.3x | — | 9.4% | -3.32% | $44.06B | /iqv-vs-medp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001668397 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Medpace Holdings Inc. (MEDP) reported GAAP revenue of $2.53B (+20.0% vs. FY2024 revenue of $2.11B , and +34.2% cumulative change since FY2023) , GAAP net income of $451.1M, operating cash flow of $713.2M, and free cash flow of $681.9M (+19.2% YoY). On the balance sheet, MEDP closed FY2025 with $1.98B in total assets against $682.4M in total debt (Altman Z-Score: 9.13, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.53B | $451.1M | $713.2M | $681.9M | $1.98B | $682.4M |
| FY2024 (FY) | 2024-12-31 | $2.11B | $404.4M | $608.8M | $572.3M | $2.10B | $573.9M |
| FY2023 (FY) | 2023-12-31 | $1.89B | $282.8M | $433.4M | $348.5M | $10.42B | $2.44B |
3. MEDP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MEDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Medpace Holdings Inc. (NASDAQ: MEDP) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $648.14 (-0.59% 1D, market cap $18.24B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, MEDP ranks #24 in composite RQD confidence.
How does MEDP compare to CRL and ICLR in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), MEDP carries a Roarable B+ (77/100 RQD), trailing P/E of 42.0x, gross margin of —, and ROIC of 27.9%. By comparison, CRL (Charles River Laboratories International Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 0.4%, cap $17.16B) and ICLR (ICON plc) posts a B grade (72/100 RQD, P/E 71.9x, ROIC 3.1%, cap $16.18B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MEDP?
Per MEDP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001668397), Medpace Holdings Inc. generated $2.53B in revenue (+20.0% YoY), $451.1M in net income, and $681.9M in free cash flow against $1.98B in total assets and $682.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 42x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MEDP trading relative to its 50-day, 200-day, and 52-week technical levels?
MEDP last traded at $648.14 (-0.59% on volume of 198,877 shares), positioning the stock +4.17% above its 50-day simple moving average ($622.17) and +22.23% above its 200-day simple moving average ($530.25). Across its 52-week range of $373.00 to $693.97, MEDP sits at the 85.7% percentile with a 14-day RSI of 52.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($601.47 to $694.81).
ROARABLE RATING BRIEF • RQD 77/100 (B+)
✓ SEC XBRL & RQD VERIFIED
MEDP — Medpace Holdings Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Medpace Holdings Inc. (MEDP) earns a live Roarable RQD composite score of 77/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $648.14 (-0.59% 1D, market capitalization $18.24B).
- Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 27.9%, gross margin of —, operating margin of 21.1%, and free cash flow yield of 3.60%.
- Whale 13F & Options Flow (15/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (11/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 9.13, Piotroski F-Score of 7/9, and Debt/Equity of 1.39x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Medpace Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Commercial Physical & Biological Research industry. The profile does not describe its specific products, customer base, or revenue model. Market capitalization is listed at $19.0B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Medpace Holdings Inc. (MEDP) reported $2.53B in annual revenue (up from $2.11B in FY2024, +20.0% YoY) and $451.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.89B revenue, $282.8M net income) through FY2025, MEDP scaled operating cash flow to $713.2M and free cash flow to $681.9M, backed by $1.98B in total assets against $682.4M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (B+ • RQD 77/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $373.00 – $693.97 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Priced at 42x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 42.0x trailing P/E and 34.0x EV/EBITDA against 21.1% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The source therefore does not map upstream suppliers, downstream customers, or sector correlations beyond the sector and industry labels. A prospective investor should note that second-order exposure cannot be assessed from this dataset.
- Key Question #1: Can MEDP sustain or expand its 21.1% operating margin and 27.9% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $2.53B and free cash flow of $681.9M, how will capital allocation balance growth reinvestment against $682.4M in total debt?
- Key Question #3: How sensitive is MEDP's 35.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
MEDP Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Medpace Holdings Inc. (MEDP) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago
Medpace Holdings, Inc. (MEDP) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Investor's Business Daily • 1d ago
Medpace Slumps On Solid Report — Where Are The 'Holes?' Investor's Business Daily report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Here’s How Much You Would Have Made Owning Medpace Holdings Stock In The Last 10 Years Benzinga report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 1d ago
Medpace: Strong Execution Faces A High-Growth Bar (NASDAQ:MEDP) Seeking Alpha report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors Yahoo Finance UK report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Medpace (NASDAQ:MEDP) reports Q3 2026 in line with expectations TradingView report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One (NASDAQ:MEDP) Seeking Alpha report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
What To Expect From Medpace’s (MEDP) Q3 Earnings Yahoo Finance report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MEDP Bull vs. Bear Conversation Board — What's Your Call at $648.14?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MEDP 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $808.49 (+24.0%)
📌 Pinned Debate Revenue grew from $1.89B to $2.53B with ROIC of 27.9%, supported by an Altman Z-Score of 9.13 and a 2025 FCF of $681.9M.
Here is why I am bullish on MEDP here at $652.01: Revenue grew from $1.89B to $2.53B with ROIC of 27.9%, supported by an Altman Z-Score of 9.13 and a 2025 FCF of $681.9M.. Compare MEDP's 21.1% operating margin and 27.9% ROIC against the rest of Biotechnology: Commercial Physical & Biological Resarch. As long as cash conversion holds up, dips toward $619.41 are getting bought.
CapAlloc_Nerd 🐂 BULL
@CashFlowKing Agree on the RQD 77/100 quality, though with 1.0 beta I'm scaling in with half-size at $652.01 and keeping dry powder in case we test $606.37.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $495.53 (-24.0%)
Spot @ $652.01 A trailing P/E of 42 and EV/EBITDA of 34 with a 3.6% FCF yield leave the valuation dependent on sustained growth, and the stock is at $
A trailing P/E of 42 and EV/EBITDA of 34 with a 3.6% FCF yield leave the valuation dependent on sustained growth, and the stock is at $677.56 near its $693.97 52-week high.. Look at the math on MEDP: paying 42.0x trailing P/E for 27.9% ROIC and 21.1% operating margins leaves zero margin of safety if Biotechnology: Commercial Physical & Biological Resarch demand softens. I'd wait for a retest of $573.77 before getting long.